<110>    Korea Research Institute of Bioscience and Biotechnology

<120>    Method for providing the information for selecting the drugs for
         treating EML4-ALK positive non-small cell lung cancer and
         compositions for treating non-small cell lung cancer resistant to
         ALK inhibitors

<130>    OP21-0090/PCT

<160>    2

<170>    KoPatentIn 3.0

<210>    1
<211>    146
<212>    PRT
<213>    Artificial Sequence

<220>
<223>    cytidine deaminase protein


<400>    1
Met Ala Gln Lys Arg Pro Ala Cys Thr Leu Lys Pro Glu Cys Val Gln
  1               5                  10                  15 

Gln Leu Leu Val Cys Ser Gln Glu Ala Lys Lys Ser Ala Tyr Cys Pro
             20                  25                  30 

Tyr Ser His Phe Pro Val Gly Ala Ala Leu Leu Thr Gln Glu Gly Arg
         35                  40                  45 

Ile Phe Lys Gly Cys Asn Ile Glu Asn Ala Cys Tyr Pro Leu Gly Ile
     50                  55                  60 

Cys Ala Glu Arg Thr Ala Ile Gln Lys Ala Val Ser Glu Gly Tyr Lys
 65                  70                  75                  80 

Asp Phe Arg Ala Ile Ala Ile Ala Ser Asp Met Gln Asp Asp Phe Ile
                 85                  90                  95 

Ser Pro Cys Gly Ala Cys Arg Gln Val Met Arg Glu Phe Gly Thr Asn
            100                 105                 110 

Trp Pro Val Tyr Met Thr Lys Pro Asp Gly Thr Tyr Ile Val Met Thr
        115                 120                 125 

Val Gln Glu Leu Leu Pro Ser Ser Phe Gly Pro Glu Asp Leu Gln Lys
    130                 135                 140 

Thr Gln
145    


<210>    2
<211>    441
<212>    DNA
<213>    Artificial Sequence

<220>
<223>    cytidine deaminase polynucleotide


<400>    2
atggcccaga agcgtcctgc ctgcaccctg aagcctgagt gtgtccagca gctgctggtt         60

tgctcccagg aggccaagaa gtcagcctac tgcccctaca gtcactttcc tgtgggggct        120

gccctgctca cccaggaggg gagaatcttc aaagggtgca acatagaaaa tgcctgctac        180

ccgctgggca tctgtgctga acggaccgct atccagaagg ccgtctcaga agggtacaag        240

gatttcaggg caattgctat cgccagtgac atgcaagatg attttatctc tccatgtggg        300

gcctgcaggc aagtcatgag agagtttggc accaactggc ccgtgtacat gaccaagccg        360

gatggtacgt atattgtcat gacggtccag gagctgctgc cctcctcctt tgggcctgag        420

gacctgcaga agacccagtg a                                                  441
